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FORTY FIVE YEARS OF ANTICOAGULANT RODENTICIDES — PAST,
PRESENT AND FUTURE TRENDS
MALCOLM R. HADLER, Managing Director, Sorex Limited, Widnes, Cheshire, WA8 8TJ, UK
ALAN P. BUCKLE, Research & Development Manager, ICI Public Health, Fernhurst, Haslcmere, Surrey, GU27 3JE, UK
ABSTRACT: The anticoagulant rodenticides were discovered in the 1940s and their advantages of efficacy and safety
quickly resulted in their use dominating the practice of rodent control in temperate countries. However, the development of
resistance to the early compounds within a decade stimulated research culminating in the invention of anew class of anticoagulant, the second generation compounds, active against resistant strains but also overall far more potent than those previously
available. A novel baiting strategy, pulsed baiting, was developed to make full use of this valuable characteristic. Pulsed baiting
has enabled the use of second generation anticoagulants in situations where early products were of limited value, particularly in
tropical agriculture. The future of this highly-successful group of compounds is reviewed in relation to resistance and the
difficulty and cost of developing further rodenticides.
Proc. 15th Vertebrate Pest Conf. (J. E. Borrecco & R. E. Marsh,
Editors) Published at University of Calif., Davis. 1992

INTRODUCTION
Few modern pesticide groups have such long a history of
successful use as the anticoagulant rodenticides. Their origin
lies in the discovery that dicoumarin was the active agent
responsible for a haemorrhagic condition found in the USA
in cattle that had been fed spoiled sweet clover hay (Link
1944).
Early interest in anticoagulants was concentrated upon
their therapeutic use for the treatment of thrombosis. Workers
at the Wisconsin Alumni Research Foundation were responsible for the isolation of dicoumarin and for the synthesis of a
number of analogues in an attempt to increase the potency
of the parent compound. The 42nd member of this series,
subsequently called warfarin, proved to be the most active.
The rodenticidal potential of these compounds seems to
have been recognised independently in the USA and in the
UK. According to Mills (1955), Link noted that warfarin
"might make a good exterminating agent" following the observation that laboratory rodents died of haemorrhage. In the
UK, workers researching dicoumarin had made a similar observation. When contacted by a pest controller who was unable to obtain rodenticides due to post-war shortages, they
handed over a sample for trial. The first controlled trials being carried out in London in 1946-47.
The unpublished reports of these trials and O'Connor
(1948) indicate that the significant advantages of anticoagulants over previously available rodenticides were recognised
remarkably quickly. In an eighteen-month period, the foundations were laid upon which all subsequent developments
took place.
Dicoumarin was introduced as a commercial rodenticidc
in the UK in 1949 and warfarin was registered for sale in
the USA in 1950. Because of its greater potency, warfarin
superseded dicoumarin and very rapidly became the dominant rodenticide, a position it was to retain on a world scale
for many years.
THE MODE OF ACTION OF
ANTICOAGULANTS
The anticoagulants represented a significant advance because they overcame nearly all of the negative aspects of their
predecessors, the acute poisons. In order to understand why

this should be it is necessary to understand the mode of action
of anticoagulants.
When the carcass of an anticoagulated rodent is analysed,
by far the largest residue of anticoagulant is found in the liver,
the site of action. Within the liver, Vitamin K is utilised to
drive the production of blood clotting factors II, VII, IX & X
by the gamma-carboxylation of glutamic acid residues of precursor proteins. Concomitant with this reaction, the active
form of vitamin K, a hydroquinone (KHj), is converted to an
inactive 2,3-epoxide. Some of this is excreted but the majority is reactivated by an epoxide reductase enzyme. The reactivated vitamin recycles and represents the major source of
vitamin K in the clotting factor synthesis cycle. Small losses
are replaced from extraneous sources, gut bacteria and from
food (Fig. 1).

Figure 1. The relationship between the metabolism and the
physiological action of Vitamin K1. (After Park 1982).
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All available anticoagulants seem to share the same site
of action; they block the epoxide reductase enzyme
(Silverman 1980). The recycling of activated vitamin K is
therefore stopped and there is insufficient incoming vitamin
K to maintain the carboxylation reaction. The production of
clotting factors is critically reduced and eventually, when the
supply of factors already present has degraded, the clotting
mechanism fails and haemorrhaging begins.
Because the mechanism is common to them all, there is
no significant difference in the time to death between anticoagulants once the enzyme is blocked. What can differ is the
time taken to achieve this. Also, once more because of their
common mode of action, the anticoagulants do not differ in
the sites at which the lethal haemorrhages occur.
The treatment of poisoning in the case of an accident is
also common to all compounds. The synthesis of clotting
factors can be restarted by the addition of appropriate amounts
of Vitamin K4. Frequent administration is necessary until the
anticoagulant has cleared. Different anticoagulants require
different treatment periods dependent upon their half-lives at
the site of action, varying from some hours for warfarin to
several weeks for the more potent products (Anon. 1988,
MacKintoshetal. 1988).
THE ADVANTAGES OF ANTICOAGULANTS
With an understanding of the mode of action of anticoagulants, it is worth reviewing the advantages that were so
quickly recognised by the early workers. These were, and still
are, the reasons why the anticoagulant group of rodenticides
came to dominate the practice of rodent control.
Prior to the introduction of anticoagulants, the only compounds available were fast-acting single-dose toxicants, such
as thallium sulphate, red squill, arsenic, zinc phosphide, and
the first purpose-built rodenticide, ANTU.
Each suffered one common fault, they produced symptoms very rapidly. Rodent behaviour is such that an individual encountering a new food for the first time will normally
test feed and may not take a substantial quantity for many
hours, or even days (Buckle et al. 1987). If the bait causes
distressing symptoms during the test feeding period, the rodent is intelligent enough to recognise cause and effect and
becomes 'poison' or 'bait shy.'
The only way to reduce the impact of bait shyness is to
prebait for several days with unpoisoned bait base and then to
substitute toxic bait when rodents have accepted the new
food. Effective prebaiting requires considerable persistence,
expertise and effort.
The potency of the acute rodenticides varied considerably, with their LD50's ranging between 5 and 100 mg/kg. In
order to ensure a lethal intake in a single feed, the concentrations of active ingredient in bails had to be high, normally
between 0.5 and 5%. The early compounds had little if any
selective toxicity and the high concentrations utilised meant
that baits represented a considerable hazard to non-target species. This problem was further exacerbated by the fact that
few had an effective antidote and their speed of effect made
treatment impractical even if one had been available. These
considerations have lead to the imposition of rigorous
restrictions on the use of acute rodenticides in many countries. The only one now widely used is zinc phosphide.
In the case of anticoagulants, the delay between the
ingestion of a potentially lethal dose and the onset of symp-

toms is such that the rodent does not recognise their relationship. In addition, the effect itself is relatively painless in most
cases. Bait shyness does not occur, prebaiting is unnecessary,
and compared to most other toxicants, anticoagulants may be
considered relatively humane (Rowsell et al. 1979).
Furthermore, a practical treatment was available in the
event of accidental ingestion and, because of their potency,
even the earliest could be used at concentrations more appropriately measured in parts per million (ppm), and therefore
palatability was inherently far less of a problem than it had
been with the fast-acting products.
THE DEVELOPMENT OF ANTICOAGULANTS
Commercial anticoagulant rodenticides are either indanediones or hydroxycoumarins, with the exception of one
thiocoumarin. Following the introduction of warfarin, a number of compounds were developed during the nineteen fifties
and these are now collectively known as the "first generation
anticoagulants." Principal amongst these were the
hydroxycoumarins, coumachlor (1951), coumafuryl (1953)
and coumatetralyl (1956). Amongst the indane-diones were
diphacinone (1952) and chlorophacinone (1961). Pindone
was first developed as an insecticide and its rodenticidal
properties were not utilised until 1953. A common feature of
the first generation compounds is that they are chronic toxicants: they are more potent if administered in small daily
doses than if given as a single dose. For example the acute
oral LD50 in rats of warfarin is variously quoted at between
10-20 mg/kg (Lund 1982) and 323 mg/kg (Hagan and
Radom-ski 1953). The sub-acute oral LD50 by contrast is
generally accepted to be about 5 daily doses of 1 mg/kg for
warfarin and for most of the first generation products. The
reason for this apparent anomaly appears to relate to their
half-lives. Yacobi and Wingard (1972) determined the biological half-life of warfarin in Sprague-Dawley rats as being
between 5 and 28 hours. Warfarin is relatively easily detoxified by the action of mixed-function oxidase enzymes and
converted to lower toxicity and easily excreted hydroxylated
metabolites (Barker et al. 1969). In order to maintain an effective concentration at the active site it is necessary constantly to renew anticoagulant removed by the action of these
enzymes.
The compounds discussed above came to dominate the
practice of rodent control world-wide in the period 19501965. They were used to such effect that it is perhaps not
surprising that resistance genes should be selected.
RESISTANCE TO FIRST GENERATION
ANTICOAGULANTS
Warfarin resistance was discovered first in Rattus
norvegicus in the UK (Boyle 1960), then in Denmark, the
Netherlands, the United States, Germany and France. Resistance was also detected in Mus domesticus (Rowe and Redfern 1965) and in Rattus rattus (Greaves et al. 1976). Concern
increased when it was found that cross-resistance existed to
all first generation anticoagulants (Rowe and Redfern 1965,
Greaves and Ayres 1969, Hadler and Shadbolt 1975).
The occurrence of resistance in all of the major commensal species to all of the anticoagulants then available rekindled
research in an area which had been dormant as a consequence
of the commercial dominance of these products. Greaves and
Ayres (1969) showed that, in a Welsh strain of resistant
150

Table 1. No-choice feeding of anticoagulant to groups of
house mice for up to 21 days.

Table 2. 10-day no-choice feeding tests of anticoagulants
against homozygons Welsh resistant Norway rats.

R. norvegicus, the resistance gene is single, dominant and
autosomal. Hermodson et al. (1969) showed that rats of this
strain, homozygous for resistance, have a dietary requirement
for vitamin K of twenty times normal. This suggested a
change of an acceptor site on the reductase enzyme such that
affinity to Vitamin K was reduced.
Unpublished work with the 2-chloro analogue of vitamin
K1 (Lowenthal and MacFarlane 1967), indicated that this
known anticoagulant was not resisted, in fact it was more
active against resistant individuals. This indicated the possibility of producing analogues which would block the resistant
enzyme and that the acceptor site corresponding to the 3phytyl side chain of vitamin K1 had not been modified.
Consideration of the structures of a number of failed
anti-malarial agents which had some anticoagulant activity
suggested that the stable substituted 3-biphenyl side chains
of these vitamin K-like l:4-naphthoquinones could be
mimicking the 3-phytyl side-chain of vitamin K.

100 times greater than that of their predecessors.

SECOND GENERATION ANTICOAGULANTS
Substitution of stereochemically similar side-chains onto
the 4-hydroxycoumarin moiety produced a series of compounds which was both effective against resistant strains and
considerably more potent than any previously used anti-coagulant (Hadler and Shadbolt 1975).
Two compounds were selected from the series for development, difenacoum and brodifacoum. These were the first
commercially available 'second generation anticoagulants.'
The term was coined to describe compounds effective against
strains resistant to previously available products. Difenacoum
was first registered in the UK in 1975, followed by
brodifacoum in 1978. Tables 1 and 2 illustrate the comparative potencies of these two compounds compared with that of
first generation products in resistant house mice and Norway
rats.
Meanwhile, in 1967, workers in France had synthesized
a series of warfarin alcohol analogues with similar side-chain
substitutions, although activity against resistant strains was
not apparently recognised until one of these, bromadiolone,
was introduced in France in 1978 (Grand 1976).
Since the introduction of difenacoum, brodifacoum and
bromadiolone, two further compounds, flocoumafen and
difethiolone, have been added to the list of commercially
available second generation anticoagulants. Apart from their
ability to control rodents resistant to previously available anticoagulants, the second generation products are characterised
by their higher overall potency (Table 3). The acute oral
toxicity of second generation products can be of the order of

A PRACTICAL PATTERN OF USE FOR THE
SECOND GENERATION ANTICOAGULANTSPULSED BAITING
The first generation products were described as chronic
rodenticides because several consecutive and substantial daily
feeds of poisoned bait were required to deliver a lethal dose.
This characteristic makes it necessary, when using them, to
maintain large quantities of bait at the site of treatment, often
for some weeks, and to visit the site frequently to replace
eaten bait to ensure the continuous availability of rodenticide.
This technique is known as surplus, or saturation, baiting
(Dubock 1984).
As well as activity against resistant rodents, the second
generation anticoagulants possess another highly advantageous characteristic. They are so potent that a lethal dose can
be delivered when an animal consumes bait on a single occasion and as only a fraction of its daily food requirement. For
example, an adult R. norvegicus will consume about 20-30
grammes of food daily and an adult M. musculus typically 25 grammes. Thus, 0.005% brodifacoum bait will deliver an
LD50 dose to a rat in only 1.3 grammes of bait and to a mouse
in only 0.2 grammes.
These observations, based on laboratory experiments
(e.g. Redfern et al. 1976), led to speculation that brodifacoum
could be potentially effective as a 'single application' rodenticide (Rennison and Dubock 1978). Trials were therefore
conducted with brodifacoum baits against Norway rats on
UK farms to test the efficacy of single bait applications of 1,4
and 7 days duration. Contrary to expectations, complete control was not achieved with any of these regimens. They
resulted in 41, 51 and 68% mortality respectively. It was
concluded that, to achieve satisfactory levels of control, bait
must be available for longer than a seven-day period because,
clearly, a proportion of rats do not feed sufficiently from bait
points in the first week to acquire a lethal dose. It was also
concluded that those rats that took bait during the first week,
and succumbed, were likely to have fed on several occasions
thereby consuming more bait than necessary to cause death.
These considerations gave rise to the concept of ‘pulsed
baiting’ (Dubock 1984) in which limited quantities of bait are
applied at approximately weekly intervals. Those animals
that feed during the early stages of the treatment consume the
available bait completely, finding none left when they return
to the bait points subsequently. They die before another application, or ‘pulse,’ of bait is laid for those animals that are
more reluctant to begin feeding on the poison. Two or more
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Table 3. Acute oral LD50 of active ingredients and baits of several anticoagulants
against Norway rats and house mice. (After Dubock 1979).

additional pulses may be required to achieve complete control of rat and mouse infestations. The mechanism of this
process was displayed during field trials of one of the more
recently introduced highly-potent second generation anticoagulants, flocoumafen (Buckle 1985).
The comparative performance of three compounds,
difenacoum, bromadiolone and brodifacoum, in pulsed baiting programmes was compared by Greaves et al. (1988).
These authors found that treatment efficacy was directly
related to the toxicity of the baits used. Thus, fewer bailing
rounds and less bait was required to achieve complete control
of resistant R. norvegicus infestations with brodifacoum baits
than with baits containing either difenacoum or bromadiolone.
The use of pulsed baiting with compounds such as
brodifacoum and flocoumafen offers valuable advantages to
the rodent control practitioner. Firstly, relatively small quantities of bait are required and less labour is needed to apply it
during baiting programmes, resulting in lower treatment costs.
Also, for periods during treatments, no bait is exposed because it has all been consumed by the target rodents (Buckle
1985), thus reducing the primary hazards of the treatment.
There is also a reduction in the quantity of bait eaten by
rodents resulting in reduced levels of residues in targets and
potentially lower secondary non-target hazard (Dubock
1984).
This system is now in use in rodent control world-wide
and is integral to the labeled use patterns of the second generation compounds. It is particularly applicable in agriculture. Smallholders cultivating tropical field crops were always
unwilling to employ the saturation baiting technique necessary to ensure the full efficacy of the first generation anticoagulants and consequently these compounds were never

widely used in tropical agriculture. Similarly, the technique
of prebaiting was never widely accepted in the use of the
acute compounds, resulting in their frequent failure (e.g. West
et al. 1972). Thus, until the introduction of the second generation compounds, tropical smallholders never had available
to them a rodenticide bait and pattern of use appropriate to
their needs. Field trials have now been conducted world-wide
to develop safe and efficient patterns of use for these products
in a very wide range of agricultural crops (e.g. Kaukeinen and
Rampaud 1986, Hoque and Olvida 1988).
SAFETY IN USE
One of the major potential benefits of the anticoagulant
rodenticides over their acute predecessors was that of
improved safety. The features which lead to this are, in
particular, the presence of an antidote, Vitamin K1, and the
slow mode of action which provides adequate time in cases of
accidental poisoning for diagnosis and treatment (Anon.
1988).
However, in spite of these safety features, as with all
pesticides, the use of anticoagulants carries with it a degree of
risk, particularly because this class of compounds contains
potent mammalian toxophores. An exacerbating factor is the
frequently commensal nature of the rodent pest problem,
which means that rodenticides are often applied peridomestically, where accidental exposures to man and his
companion and domestic animal are likely. Additionally, 'rat
poisons' are attractive to those who would mis-use them as
vertebrate killing agents outside labeled use patterns and for
unlawful purposes unrelated to rodent control.
In spite of all these factors, the anticoagulant rodenticides have a remarkable history of safe and efficient use over
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a period exceeding 40 years. Few published records exists
which place this history into context but, perhaps, the most
fully documented evidence on accidental exposure to harmful substances is published in the USA. Litovitz et al. (1989)
record that, of more than one million human exposures, only
3.8% were associated with pesticides; a category which includes rodenticides as only a minor component. Exposures to
analgesics, cleaning agents and cosmetics by far exceed in
number exposures to pesticides.
Although the number of exposures to rodenticides is
relatively small, the demographic profile of these incidents is
of great interest to those attempting to develop even safer
products. The data presented by Litovitz et al. (1989) is typical in showing that the vast majority of exposures are via the
oral route, involve children under the age of six and occur,
presumably, when they accidentally encounter rodenticide
bait placements. A major advance in ensuring a favourable
outcome in such cases is the use of a human taste deterrent in
rodenticidal preparations (Johnson 1988). This substance,
‘Bitrex,’ is not perceived by rodents but its inclusion in bails
at an appropriate concentration renders them highly objectionable to humans (Kaukeinen and Buckle, these Proceedings). This will serve to reduce the quantity of bait ingested
during accidental exposures, although the numbers of
recorded exposures may actually increase when baits contain
'Bitrex' because their unpleasant taste will more likely cause
'consumers' to report the episode.
Companion animals are also occasionally exposed to rodenticides because of the often close association between the
places where they are housed and the sites of rodent
infestation. Care in bait placement, the use of bait stations of
suitable construction and baits with low intrinsic palatability
to companion animals will serve to reduce the frequency and
severity of these exposures to very low levels but it is
impossible to eliminate this risk altogether.
ENVIRONMENTAL IMPACT
It is unlikely that anticoagulant rodenticides will have
any major adverse environmental impact (Kaukeinen 1982).
Their mode of use generally involves the localised placement, often within bait containers, of small quantities of bait
with very low toxicant loadings. The contamination of either
aquatic or soil systems with these compounds remains therefore a remote possibility envisaged only in the event of serious mis-use.
However, the most problematic aspect of the potential of
anticoagulants to have an impact is the hazard they may pose
to animals that prey upon poisoned rodents or scavenge their
dead bodies. All the second-generation compounds arc
equally persistent, and even some of the earlier compounds
are retained in animal tissues at sub-lethal levels for relatively
long periods (Parmar et al. 1987, Huckle et al. 1989). It is
known, therefore, that where target rodents are the dietary
mainstay of a carnivorous non-target species, individuals of
the latter species may be at risk (e.g., Hegdal and Colvin
1988). To date, however, there is no indication that the occasional mortalities caused by anticoagulants have had any affect on non-target populations, as such losses are rapidly made
good by breeding (Kaukeinen 1982, North 1985).
One of the most thoroughly investigated interactions is
that between Barn owls and anticoagulant rodenticides in the
UK. In spite of the prolonged and intensive use of com-

pounds such as coumatetralyl, difenacoum, bromadiolone and
brodifacoum, there is no evidence that this has been to the
detriment of Barn Owl populations (Percival, 1990).
However, there is scope for studies to monitor the population
levels of non-target animals, particularly predatory birds, and
for the development of potent anticoagulants that are more
rapidly eliminated from animal tissues than those currently
available.
THE FUTURE
Five highly potent second generation anticoagulants have
been commercialised and three of them, brodifacoum,
flocoumafen and difethiolone, each to a greater or lesser extent, can be said to possess the capability of killing rodents
after a single feed. These three compounds have acute oral
LD50S to R. norvegicus in the range 0.2-0.4 mg/kg. It is the
experience of one of us (MRH), having worked with numerous experimental analogues, that none with significantly
higher toxicity has ever been found. It appears that, after 45
years of development of anticoagulants with progressively
greater potency, the upper limit has at last been reached.
Although the chronic action of the anticoagulant rodenticides is an advantage in preventing the development of bait
shyness, it also has the disadvantage that animals which have
consumed a lethal dose of poison may continue to feed on
bait for several subsequent days. This is both wasteful and
increases secondary hazard. It would be beneficial to have a
potent anticoagulant which caused death after, say, 2-3 days
rather than the 5-6 days that is characteristic of the presently
available compounds. However, the onset of symptoms of
anticoagulation and death occurs only after the reservoir of
various blood clotting factors have been fully depleted. This
mechanism is fundamental to the mode of action of all compounds and it seems, at the moment, unlikely that an anticoagulant with a faster action can be produced.
Several of the second-generation anticoagulants have
been used extensively world-wide for 15 years or more. This
constitutes a substantial selection pressure favouring the
emergence of resistant strains. So far, however, resistance to
these compounds is very localised. In southern-central England populations of R. norvegicus resistant to difenacoum are
found in a locality coincident with a long- established area of
warfarin resistance (Greaves et al. 1982). Resistance to both
difenacoum and bromadiolone is present in Norway rats in
Denmark (Lund 1984) and the Danish Pest Infestation laboratory has also identified populations of House mice resistant
to the same compounds (Anon. 1990). In both foci it is possible, in laboratory tests, to demonstrate that rodents are less
sensitive to the more potent compound brodifacoum (e.g. Gill
and MacNicoll 1991), although this altered level of tolerance
falls short of resistance in practical terms.
There is much speculation on what the future holds in
terms of resistance to the second generation anticoagulants.
Some workers feel that the levels of resistance described
above presage the development of ever more resistant populations of rodents. There is an alternative view, however, that
resistance may have reached an upper limit in the levels presently observed in southern England (Greaves and CullenAyres 1988). This is because possession of resistance genes
carries with it the cost of impaired ability to synthesize Vitamin K. Some resistant rodents require twenty times more
dietary Vitamin K than their susceptible counterparts and
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further development of resistance may thus be physiologically self-limiting. Whatever the future holds for resistance in
temperate countries where anticoagulant use is intensive, it
seems unlikely that resistance to the second generation compounds will become a serious practical problem in the tropics. This is implied by the fact that resistance to the first
generation compounds, widespread in North America and in
many European countries, is of very limited importance
elsewhere.
Given that anticoagulants are designed to be mammalian
toxicants, their record of safety in use is impressive. Significant selective toxicity has been achieved in favour of many
non-target animals (Dubock and Kaukeinen 1978, Bowler et
al. 1984, Lechevin and Poche 1988) but there would still
seem to be a benefit in developing a product with even greater
specificity. However, the increasingly rigourous regulatory
requirements currently being introduced in the USA, Europe
and elsewhere have caused companies to direct resources
towards the defense of existing compounds rather than to the
development of new ones. Furthermore, development costs
have soared. For example, the cost of introducing
flocoumafen during the 1980s was more than ten times
greater, in real terms, than that of developing difenacoum a
decade earlier. These costs, and the existence already of five
highly potent compounds, would make it necessary to consider carefully the commercial justification for the development of a new, more specific anticoagulant, even if such a
compound was technically feasible.
Anticoagulant rodenticides have a long history of effective and safe use world-wide. It seems likely that those
currently available will continue to dominate the practice of
rodent control for many years to come.
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